Related Experiment Video
Updated: May 6, 2026

Gene Expression Profiling of Infecting Microbes Using a Digital Bar-coding Platform
Published on: January 13, 2016
ICU care through NGS - Based identification of infectious agents: A comparative study
Aishwariya Ramanathan1, Anusuya Marimuthu1, Lalanika M Abayasekara2
1Micro Genomics India Pvt Ltd, 16, Wallace Garden First street, Thousand lights, Chennai, 600006, India.
Next-generation sequencing assays Bactfast® and Fungifast® show promise for diagnosing sepsis in intensive care units (ICUs). Bactfast® demonstrated high sensitivity and specificity, potentially improving patient outcomes in critical sepsis cases.
Area of Science:
- Clinical microbiology and infectious diseases.
- Genomic technologies for pathogen identification.
- Intensive care unit (ICU) diagnostics and patient management.
Background:
- Sepsis is a leading cause of mortality, accounting for 20% of global deaths and a significant proportion of ICU admissions.
- Accurate and rapid diagnosis of causative pathogens in sepsis is challenging due to polymicrobial infections, commensals, and contaminants.
- Traditional methods like culture and PCR have limitations in overcoming these diagnostic complexities.
Purpose of the Study:
- To evaluate the efficacy of Bactfast® and Fungifast® assays as advanced diagnostic tools for non-resolving ICU sepsis.
- To assess the ability of next-generation sequencing (NGS)-based assays to differentiate true pathogens from commensals and contaminants.
- To determine the diagnostic performance of Bactfast® and Fungifast® in a real-world ICU setting.
Main Methods:
- A retrospective study was conducted across four ICUs in Chennai, India.
- Samples were processed using Bactfast® and Fungifast® assays at a central NGS facility.
- Results were correlated with conventional microbiological testing and clinical data by a multidisciplinary team.
Main Results:
- The Bactfast® assay achieved a sensitivity of 94.1% and a specificity of 86.6%, outperforming previous data.
- Bactfast® showed positive correlation with clinical confirmation, indicating reliable pathogen identification.
- Fungifast® demonstrated high specificity (99.4%), but further research is needed due to a low number of positive fungal cultures.
Conclusions:
- Bactfast® offers unbiased pathogen identification, with potential to reduce mortality and morbidity in life-threatening ICU sepsis.
- The NGS-based approach effectively distinguishes pathogens from contaminants and commensals.
- Further investigation of Fungifast® using diverse methodologies and larger sample sizes is warranted to fully evaluate its diagnostic sensitivity.
Related Concept Videos
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Urine Studies II: Urine Culture and Sensitivity Test
Automated Microbial Diagnostics

